Search Results

Treatment of Major DSM-5 Disorders, Including Addiction, Depression and Anxiety, With Sub-Hallucinogenic Mescaline Doses Extraction Technology Delivering Higher Yields and Greater Purity Frankfurt Stock Exchange Ticker Symbol Changed to “HANF” Extension of LOI with CWE European Holdings (dba Hanf.com)

Neural Therapeutics Inc. (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioids, wishes to announce that Dr. Kelly Narine and Professor Jason Dyck have resigned as directors of Neural, and Dr. Carlos Davidovich was appointed as a new director.

Toronto, Ontario--(Newsfile Corp. - May 8, 2024) - Neural Therapeutics Inc. (“Neural” or the “Company”), an ethnobotanical drug discovery company dedicated to developing therapeutic drugs for mental ailments related to substance use disorders...